What is the current valuation of the Schistosomiasis Disease Market?

As of 2024, the Schistosomiasis Disease Market was valued at approximately 120.55 USD Billion. Read More

What is the projected market valuation for the Schistosomiasis Disease Market in 2035?

The Schistosomiasis Disease Market is projected to reach approximately 182.85 USD Billion by 2035. Read More

What is the expected CAGR for the Schistosomiasis Disease Market during the forecast period 2025 - 2035?

The expected CAGR for the Schistosomiasis Disease Market during the forecast period 2025 - 2035 is 3.86%. Read More

Which companies are considered key players in the Schistosomiasis Disease Market?

Key players in the Schistosomiasis Disease Market include Merck & Co., Bayer AG, GlaxoSmithKline, Sanofi, Johnson & Johnson, AbbVie Inc., Novartis AG, and Pfizer Inc. Read More

What are the main types of Schistosomiasis and their market valuations?

The main types of Schistosomiasis include Intestinal Schistosomiasis valued at 30.0 - 45.0 USD Billion, Urogenital Schistosomiasis at 40.0 - 60.0 USD Billion, Dermatological Schistosomiasis at 25.0 - 35.0 USD Billion, and Hepatic Schistosomiasis at 25.55 - 42.85 USD Billion. Read More

What are the leading diagnosis methods for Schistosomiasis and their market values?

Leading diagnosis methods include Serological Testing valued at 30.0 - 45.0 USD Billion, Stool Examination at 25.0 - 35.0 USD Billion, Urine Examination at 20.0 - 30.0 USD Billion, and Imaging Techniques at 15.55 - 22.85 USD Billion. Read More

What treatment methods are available for Schistosomiasis and their market valuations?

Treatment methods include Anthelminthic Therapy valued at 40.0 - 60.0 USD Billion, Supportive Therapy at 30.0 - 45.0 USD Billion, Surgical Intervention at 20.0 - 30.0 USD Billion, and Preventive Measures at 30.55 - 47.85 USD Billion. Read More

Which end-user segments are prominent in the Schistosomiasis Disease Market?

Prominent end-user segments include Hospitals valued at 30.0 - 45.0 USD Billion, Clinics at 25.0 - 40.0 USD Billion, Research Institutions at 20.0 - 30.0 USD Billion, and Homecare Settings at 45.55 - 67.85 USD Billion. Read More

How does the market for Schistosomiasis compare across different treatment methods?

The market for Schistosomiasis treatment methods indicates that Anthelminthic Therapy holds the largest share, followed by Supportive Therapy, Surgical Intervention, and Preventive Measures. Read More

What trends are expected to shape the Schistosomiasis Disease Market in the coming years?

Trends likely to shape the Schistosomiasis Disease Market include advancements in diagnostic techniques, increased awareness of treatment options, and a growing focus on preventive measures. Read More

Schistosomiasis Disease Market

ID: MRFR/HC/37343-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Schistosomiasis Disease Market Research Report By Type of Schistosomiasis (Intestinal Schistosomiasis, Urogenital Schistosomiasis, Dermatological Schistosomiasis, Hepatic Schistosomiasis), By Diagnosis Method (Serological Testing, Stool Examination, Urine Examination, Imaging Techniques), By Treatment Method (Anthelminthic Therapy, Supportive Therapy, Surgical Intervention, Preventive Measures), By End User (Hospitals, Clinics, Research Institutions, Homecare Settings) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type of Schistosomiasis (USD Billion)
  1. 4.1.1 Intestinal Schistosomiasis
  2. 4.1.2 Urogenital Schistosomiasis
  3. 4.1.3 Dermatological Schistosomiasis
  4. 4.1.4 Hepatic Schistosomiasis
2. 4.2 Healthcare, BY Diagnosis Method (USD Billion)
  1. 4.2.1 Serological Testing
  2. 4.2.2 Stool Examination
  3. 4.2.3 Urine Examination
  4. 4.2.4 Imaging Techniques
3. 4.3 Healthcare, BY Treatment Method (USD Billion)
  1. 4.3.1 Anthelminthic Therapy
  2. 4.3.2 Supportive Therapy
  3. 4.3.3 Surgical Intervention
  4. 4.3.4 Preventive Measures
4. 4.4 Healthcare, BY End User (USD Billion)
  1. 4.4.1 Hospitals
  2. 4.4.2 Clinics
  3. 4.4.3 Research Institutions
  4. 4.4.4 Homecare Settings
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Merck & Co. (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bayer AG (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 GlaxoSmithKline (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Sanofi (FR)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Johnson & Johnson (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AbbVie Inc. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis AG (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Pfizer Inc. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
4. 6.4 US MARKET ANALYSIS BY DIAGNOSIS METHOD
5. 6.5 US MARKET ANALYSIS BY TREATMENT METHOD
6. 6.6 US MARKET ANALYSIS BY END USER
7. 6.7 CANADA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
8. 6.8 CANADA MARKET ANALYSIS BY DIAGNOSIS METHOD
9. 6.9 CANADA MARKET ANALYSIS BY TREATMENT METHOD
10. 6.10 CANADA MARKET ANALYSIS BY END USER
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
13. 6.13 GERMANY MARKET ANALYSIS BY DIAGNOSIS METHOD
14. 6.14 GERMANY MARKET ANALYSIS BY TREATMENT METHOD
15. 6.15 GERMANY MARKET ANALYSIS BY END USER
16. 6.16 UK MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
17. 6.17 UK MARKET ANALYSIS BY DIAGNOSIS METHOD
18. 6.18 UK MARKET ANALYSIS BY TREATMENT METHOD
19. 6.19 UK MARKET ANALYSIS BY END USER
20. 6.20 FRANCE MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
21. 6.21 FRANCE MARKET ANALYSIS BY DIAGNOSIS METHOD
22. 6.22 FRANCE MARKET ANALYSIS BY TREATMENT METHOD
23. 6.23 FRANCE MARKET ANALYSIS BY END USER
24. 6.24 RUSSIA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
25. 6.25 RUSSIA MARKET ANALYSIS BY DIAGNOSIS METHOD
26. 6.26 RUSSIA MARKET ANALYSIS BY TREATMENT METHOD
27. 6.27 RUSSIA MARKET ANALYSIS BY END USER
28. 6.28 ITALY MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
29. 6.29 ITALY MARKET ANALYSIS BY DIAGNOSIS METHOD
30. 6.30 ITALY MARKET ANALYSIS BY TREATMENT METHOD
31. 6.31 ITALY MARKET ANALYSIS BY END USER
32. 6.32 SPAIN MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
33. 6.33 SPAIN MARKET ANALYSIS BY DIAGNOSIS METHOD
34. 6.34 SPAIN MARKET ANALYSIS BY TREATMENT METHOD
35. 6.35 SPAIN MARKET ANALYSIS BY END USER
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS METHOD
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY TREATMENT METHOD
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USER
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
42. 6.42 CHINA MARKET ANALYSIS BY DIAGNOSIS METHOD
43. 6.43 CHINA MARKET ANALYSIS BY TREATMENT METHOD
44. 6.44 CHINA MARKET ANALYSIS BY END USER
45. 6.45 INDIA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
46. 6.46 INDIA MARKET ANALYSIS BY DIAGNOSIS METHOD
47. 6.47 INDIA MARKET ANALYSIS BY TREATMENT METHOD
48. 6.48 INDIA MARKET ANALYSIS BY END USER
49. 6.49 JAPAN MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
50. 6.50 JAPAN MARKET ANALYSIS BY DIAGNOSIS METHOD
51. 6.51 JAPAN MARKET ANALYSIS BY TREATMENT METHOD
52. 6.52 JAPAN MARKET ANALYSIS BY END USER
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS METHOD
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY TREATMENT METHOD
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USER
57. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
58. 6.58 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS METHOD
59. 6.59 MALAYSIA MARKET ANALYSIS BY TREATMENT METHOD
60. 6.60 MALAYSIA MARKET ANALYSIS BY END USER
61. 6.61 THAILAND MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
62. 6.62 THAILAND MARKET ANALYSIS BY DIAGNOSIS METHOD
63. 6.63 THAILAND MARKET ANALYSIS BY TREATMENT METHOD
64. 6.64 THAILAND MARKET ANALYSIS BY END USER
65. 6.65 INDONESIA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
66. 6.66 INDONESIA MARKET ANALYSIS BY DIAGNOSIS METHOD
67. 6.67 INDONESIA MARKET ANALYSIS BY TREATMENT METHOD
68. 6.68 INDONESIA MARKET ANALYSIS BY END USER
69. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
70. 6.70 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS METHOD
71. 6.71 REST OF APAC MARKET ANALYSIS BY TREATMENT METHOD
72. 6.72 REST OF APAC MARKET ANALYSIS BY END USER
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
75. 6.75 BRAZIL MARKET ANALYSIS BY DIAGNOSIS METHOD
76. 6.76 BRAZIL MARKET ANALYSIS BY TREATMENT METHOD
77. 6.77 BRAZIL MARKET ANALYSIS BY END USER
78. 6.78 MEXICO MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
79. 6.79 MEXICO MARKET ANALYSIS BY DIAGNOSIS METHOD
80. 6.80 MEXICO MARKET ANALYSIS BY TREATMENT METHOD
81. 6.81 MEXICO MARKET ANALYSIS BY END USER
82. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
83. 6.83 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS METHOD
84. 6.84 ARGENTINA MARKET ANALYSIS BY TREATMENT METHOD
85. 6.85 ARGENTINA MARKET ANALYSIS BY END USER
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS METHOD
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT METHOD
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS METHOD
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT METHOD
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS METHOD
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT METHOD
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER
99. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
100. 6.100 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS METHOD
101. 6.101 REST OF MEA MARKET ANALYSIS BY TREATMENT METHOD
102. 6.102 REST OF MEA MARKET ANALYSIS BY END USER
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY TYPE OF SCHISTOSOMIASIS, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY TYPE OF SCHISTOSOMIASIS, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY TREATMENT METHOD, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY TREATMENT METHOD, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY END USER, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.2.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.2.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.2.4 BY END USER, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.3.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.3.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.3.4 BY END USER, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.4.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.4.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.4.4 BY END USER, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.5.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.5.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.5.4 BY END USER, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.6.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.6.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.6.4 BY END USER, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.7.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.7.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.7.4 BY END USER, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.8.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.8.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.8.4 BY END USER, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.9.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.9.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.9.4 BY END USER, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.10.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.10.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.10.4 BY END USER, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.11.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.11.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.11.4 BY END USER, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.12.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.12.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.12.4 BY END USER, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.13.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.13.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.13.4 BY END USER, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.14.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.14.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.14.4 BY END USER, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.15.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.15.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.15.4 BY END USER, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.16.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.16.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.16.4 BY END USER, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.17.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.17.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.17.4 BY END USER, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.18.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.18.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.18.4 BY END USER, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.19.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.19.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.19.4 BY END USER, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.20.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.20.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.20.4 BY END USER, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.21.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.21.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.21.4 BY END USER, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.22.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.22.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.22.4 BY END USER, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.23.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.23.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.23.4 BY END USER, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.24.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.24.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.24.4 BY END USER, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.25.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.25.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.25.4 BY END USER, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.26.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.26.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.26.4 BY END USER, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.27.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.27.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.27.4 BY END USER, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.28.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.28.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.28.4 BY END USER, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.29.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.29.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.29.4 BY END USER, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
  2. 7.30.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.30.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
  4. 7.30.4 BY END USER, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Schistosomiasis Disease Market Segmentation

Schistosomiasis Disease Market By Type of Schistosomiasis (USD Billion, 2025-2035)

Intestinal Schistosomiasis
Urogenital Schistosomiasis
Dermatological Schistosomiasis
Hepatic Schistosomiasis

Schistosomiasis Disease Market By Diagnosis Method (USD Billion, 2025-2035)

Serological Testing
Stool Examination
Urine Examination
Imaging Techniques

Schistosomiasis Disease Market By Treatment Method (USD Billion, 2025-2035)

Anthelminthic Therapy
Supportive Therapy
Surgical Intervention
Preventive Measures

Schistosomiasis Disease Market By End User (USD Billion, 2025-2035)

Hospitals
Clinics
Research Institutions
Homecare Settings

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”